C-01 An Evaluative Study of a Cognitive Training Program on Cognitive Outcomes in Older Adults with Moderate to Severe Cognitive Impairment

Objective

Because medical interventions for persons with dementia have limited effectiveness, there is a need to evaluate non-pharmacological interventions designed to support individuals with cognitive impairment. Cognitive training is a non-pharmacological approach aimed at improving or maintaining cognitive functioning through practice. The current study evaluated the effects of a cognitive training program in older adults with moderate to severe cognitive impairment.

Method

Data were collected from seven females and one male with a mean age of 83.1 who met criteria for moderate to severe cognitive impairment as defined by a Modified Mini-Mental Status Exam score between 49-77 (M = 54.5). Participants were recruited from two organizations that provide housing and supportive services for older adults with cognitive impairments. Cognitive changes were measured using the Repeatable Battery for the Assessment of Neuropsychological Status-Update.

Results

Effect sizes (Cohen’s d) were calculated to measure the magnitude of change from pre- to post-intervention. Results indicated no change in the domains of immediate memory (d = -0.08) and attention (d = -0.17). A medium effect size was found in delayed memory (d = 0.68), while large effect sizes were found in language (d = 1.70), visuospatial/constructional (d = 0.89), and the total scale index (d = 1.40).

Conclusion

The results provide tentative support for the effectiveness of cognitive training in maintaining or improving some cognitive abilities in older adults with moderate to severe cognitive impairment. Further research with larger samples sizes and control groups are necessary to verify these preliminary findings and to determine if benefits generalize to everyday life.

A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer

3094

Background: SRA737 is a potent, highly selective and orally-bioavailable inhibitor of checkpoint kinase 1 (Chk1). SRA737-01 was designed to investigate the safety and tolerability of continuous, daily dosing with SRA737 and to evaluate preliminary efficacy in expansion cohorts of prospectively-selected genetically-defined subjects with advanced tumors. Methods: The escalation phase employed an accelerated titration design starting at 20 mg administered orally in 28-day cycles. Incremental 100% dose escalations in single-subject cohorts were followed by a rolling-6 design once SRA737-related ≥ Grade 2 toxicity was observed during Cycle 1. The expansion phase enrolled subjects prospectively selected by next-generation sequencing with: high grade serous ovarian, colorectal, metastatic castration-resistant prostate, non-small cell lung, and head and neck cancers. Results: In escalation, 18 subjects received SRA737 in 9 dose level cohorts, from 20 to 1300 mg QD; median treatment duration 62.5 days (range 1 to 226). Of these subjects, 3 experienced dose limiting toxicity (DLT; inability to receive 75% of the planned dose); 2 at 1300 mg QD due to gastrointestinal intolerability and 1 at 500 mg BID due to thrombocytopenia. The maximum tolerated dose (MTD) was established at 1000 mg QD or 500 mg BID. The Cmax and AUC0-24 at 1000 mg QD were 2391 ng/mL and 26795 ng∙h/mL respectively and the Cmin (411 ng/mL) exceeded that determined in preclinical models to be effective. Doses ≥ 300 mg QD also exceeded this level. Of 462 subjects prospectively screened for genetic alterations associated with Chk1 sensitivity, 93 were enrolled in expansion across all tumor types. Overall, the most commonly reported treatment-emergent adverse events were diarrhea (70%), nausea (64%), vomiting (51%), and fatigue (47%); the majority were of mild to moderate severity. Conclusions: In this first-in-human trial of SRA737 monotherapy, the MTD was 1000 mg/day and based on overall tolerability and PK, the recommended Phase 2 dose is 800 mg/day. The successful enrollment of prospectively-selected genetically-defined subjects will allow response data to be correlated with genomic profiles hypothesized to confer sensitivity to Chk1 inhibition. Clinical trial information: NCT02797964.

Effects of morphine glucuronides on the function of opioid receptors in human SK-N-SH cells

Morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) are active metabolites of morphine. The effects of M3G and M6G on the opioid receptor transduction system has not yet been fully elucidated. Formation of cAMP after treatment with various doses of morphine, M3G, and M6G was studied. M6G and morphine, but not M3G, showed a dose dependent inhibition of cAMP accumulation. Naloxone blocked the inhibitory effect of M6G, M3G, and morphine. Pretreatment with M3G did not change the effects of morphine and M6G. The G-protein inhibitor PTX, prevented morphine, M3G, and M6G effects on cAMP. M3G and M6G vary in their ability to interact with the opioid receptor effector system. Inhibition of cAMP evoked by activation of opioid receptors and inhibitory G-proteins may play a role in the actions of M6G and M3G.

Systemic absorption of lignocaine ointment from tracheal tubes

Arterial plasma concentrations of lignocaine were studied in fifteen adult patients following insertion of a tracheal tube whose cuff area was smeared with 5% lignocaine ointment. Twelve patients had 2 ml of ointment (114 mg) and samples were taken every 5 minutes until 30 minutes and in eight of the 12 patients at 40, 50 and 60 minutes after insertion and inflation of the tracheal tube and cuff. Three patients had 1 ml of ointment on the tube and were studied over 60 minutes. Plasma concentrations were determined using gas liquid chromatography. In the 2 ml lignocaine group mean plasma lignocaine levels were 1.9 (SD 0.9) micrograms/ml at 10 minutes, 2.3 (SD 0.8) micrograms/ml at 20 minutes, 2.3 (SD 0.8) micrograms/ml at 30 minutes and 1.7 (SD 1.0) micrograms/ml at 60 minutes. After 1 ml of lignocaine, levels were 1.2 (SD 0.1) micrograms/ml at 10 minutes, 1.1 (SD 0.7) micrograms/ml at 20 minutes, 0.8 (SD 0.3) micrograms/ml at 30 minutes and 0.75 (SD 0.1) micrograms/ml at 60 minutes.

Ventilatory effects of nitrous oxide during continuous infusion of fentanyl or alfentanil

Two groups of eight patients received infusions of either fentanyl at 3 micrograms kg-1 h-1 or alfentanil at 20 micrograms kg-1 h-1 as supplements to 66% N2O in oxygen anaesthesia, during and after body surface surgery. At the end of surgery, the N2O was reduced to 50% and after measurement of ventilatory frequency, minute ventilation, and the ventilatory response to carbon dioxide, N2O was discontinued. The opioid infusions were continued for a further hour and the ventilatory measurements repeated. Both sets of measurements were compared with preoperative values. Minute ventilation (P less than 0.01), frequency (P less than 0.01) and the response to carbon dioxide (P less than 0.01) were reduced during the infusion of fentanyl with N2O; with fentanyl alone, minute ventilation (P less than 0.05) and the response to carbon dioxide (P less than 0.01) were reduced but to a lesser degree. The elimination of nitrous oxide from the inspired gas mixture produced an increase in frequency (P less than 0.05) and increases in the slope (P less than 0.01) and ventilation at 7.3 kPa (P less than 0.025) of the carbon dioxide response curve. Minute ventilation (P less than 0.01) frequency (P less than 0.05) and response to carbon dioxide (P less than 0.01) were all reduced during the infusion of alfentanil with nitrous oxide; with alfentanil alone, minute ventilation (P less than 0.01), tidal volume (P less than 0.05), the slope (P less than 0.025) and the ventilation at 7.3 kPa (P less than 0.01) of the carbon-dioxide response curve were still reduced.(ABSTRACT TRUNCATED AT 250 WORDS)

Ventilatory depression related to plasma fentanyl concentrations during and after anesthesia in humans

Twenty-four patients were allocated randomly into four groups for the study of the pharmacokinetics of, and effects on postoperative ventilation of, two doses of fentanyl (10 micrograms/kg or 25 micrograms/kg) administered at the start of general anesthesia in which ventilation was controlled at a fixed volume, but arterial PCO2 was adjusted to a range of either 38-42 torr, or 20-25 torr. During the first 2 hr after anesthesia, ventilatory depression (CO2 responsiveness decreased to less than 50% of awake values, PaCO2 greater than 48 torr) occurred only in patients who had received 25 micrograms/kg fentanyl, and was more marked in patients who were hyperventilated to a low PaCO2 during anesthesia. Plasma fentanyl concentrations associated with 50% depression of CO2 responsiveness were in the range 1.5-3.0 ng/ml, the lower values found in patients hyperventilated to a low PaCO2. Whole-body clearance of fentanyl was significantly decreased by hypocapnic hyperventilation.

Hepatic function after anaesthesia for major vascular reconstructive surgery

Three groups of patients received Althesin, minaxolone or di-isopropyl phenol to supplement 67% nitrous oxide in oxygen. A fourth group receiving halothane to supplement nitrous oxide in oxygen acted as a control. Hepatic function tests were measured before operation and on days 1, 3, 5 and 7 after major vascular reconstructive surgery. There were significant increases to a mean value above the upper limit of normal in aspartate amino-transferase activity by day 3 in all groups. Total lactic dehydrogenase activity increased in the patients receiving Althesin, minaxolone and halothane. No change was seen in the alkaline phosphatase in any of the study groups. Gamma glutamyl transpeptidase increased in all groups, but the mean value at day 7 was not greater than the upper limit of normal. The mean activity of ornithine carbamoyl transpeptidase showed no change in any group throughout the study period. Two of the patients receiving minaxolone suffered cholestatic jaundice during the first month. These results suggest that anaesthesia with Althesin or di-isopropyl phenol results in enzyme changes similar to those seen in a comparable group of patients receiving halothane to supplement nitrous oxide in oxygen anaesthesia.